Our Content Hub

Strategic Capital Supports Pivotal-Stage Execution

Strengthening AVIM Therapy’s Regulatory Pathway: A Second FDA Breakthrough Device Designation

From Blood Pressure Reduction to Cardiac Function: What New AVIM Therapy Data Signal

Our Clinical Vision: AVIM Therapy for Hypertensive Heart Disease

When Partnership Drives Progress: Reflections on the Vivasure Journey

2025 Reflections from OBIO CEO

Investor Blog: OBIO at ICI 2025 - The Triangle of Innovation in Action

Shareholder Call Series: Part 3 — Key Themes from the Analyst Q&A

Shareholder Call Series: Part 2 — Advancing Pivotal Programs Toward Major Clinical and Regulatory Milestones

Shareholder Call Series: Part 1 — Building a Strong Capital Base and Strategic Alignment for Long-Term Growth

Virtue SAB: Redefining Arterial Drug-Delivery — and Why It Matters for Shareholders

Unlocking the Value of Virtue SAB with the Achievement of Two Major Milestone

OBIO | AVIM Publications and Presentations Supplementary Explanation

Strategic Recaps: The Power of Partnership and Future of AVIM Therapy

A Closer Look at Last Week’s Financing News — and What Comes Next

OBIO | NYSE Interview: A Shareholder Guide and Key Takeaways

AVIM Therapy: A Purpose-Built Solution for a Large, Underserved Patient Population

First Quarter 2025 Business Highlights

AVIM Therapy Patent Portfolio Reaches New Milestone

Virtue SAB IDE Approval and What It Means for OBIO Shareholders

Yesterday’s FDA Breakthrough Device Designation News

AVIM Therapy Breakthrough Device Designation Shareholder Implications

All posts

Posts by Topic

Recent Posts

Orchestra BioMed logo

© 2026 Orchestra BioMed Inc. Virtue®, BackBeat CNT™ FreeHold Duo®, FreeHold Trio® and Orchestra BioMed™ are trademarks of Orchestra BioMed.
All other trademarks are trademarks of their respective owners.
SM-0020 Rev 01

Disclaimer